Table 2 Crude and age- and sex-standardized prevalence and incidence of psoriatic arthritis in Israel by year (2016–2022)
From: Epidemiological trends in psoriatic arthritis: a comprehensive population-based study
Prevalence of PsA | Incidence of PsA | ||||||
|---|---|---|---|---|---|---|---|
Year | Total population | PSA cases (n) | Crude prevalence (%) | Standardized prevalence (95% CI) | New PSA (n) | Crude incidence | Standardized incidence ( 95% CI) |
2016 | 2,898,800 | 4,782 | 0.165 | 0.148 (0.146–1.15) | 374 | 12.98 | 12.40 (11.1–13.7) |
2017 | 2,934,164 | 5,081 | 0.173 | 0.155 (0.153–0.157) | 389 | 13.36 | 13.05 (11.7–14.4) |
2018 | 2,974,138 | 5,372 | 0.181 | 0.161 (0.159–0.163) | 374 | 12.66 | 12.25 (11-13.5) |
2019 | 3,015,102 | 5,807 | 0.193 | 0.172 (0.17–0.174) | 531 | 17.75 | 17.07 (15.6–18.5) |
2020 | 3,057,362 | 6,225 | 0.204 | 0.182 (0.18–0.184) | 532 | 17.51 | 16.74 (15.3–18.2) |
2021 | 3,092,199 | 6,602 | 0.214 | 0.190 (0.188–0.193) | 488 | 15.90 | 15.46 (14-16.8) |
2022 | 3,133,500 | 6,930 | 0.221 | 0.197 (0.194-0.2) | 432 | 13.90 | 13.54 (12.2–14.8) |